ITROMAC-200 CAPSULE

MECHANISM OF ACTION:
Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

INDICATIONS:
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

DOSAGE:
As directed by the physician.

CONTRA-INDICATIONS:
Contraindicated in patients who have shown hypersensitivity to Itraconazole or the excipients.

SIDE EFFECTS:
Headache, Dizziness, Nausea, Vomiting, Upset Stomach, Constipation and Muscle aches.

STORAGE:
Store in a cool and dry place. Protect from light.

PRESENTATION:
10x1x10 Capsules in a cardboard carton.

BARCODE:
(01)08906044108820
(01)18906044108827
(01)28906044108824